| abstract |
The present invention provides the use of monoclonal MASP-2 inhibitory antibody or antigen-binding fragment thereof for inhibiting MASP-2-dependent complement activation in the preparation of medicines, and the medicines are used to treat patients with atypical hemolytic uremic syndrome (aHUS) ), wherein the MASP-2 antibody or antigen-binding fragment thereof specifically binds to a portion of SEQ ID NO: 6 and selectively inhibits MASP-2-dependent complement activation while maintaining the integrity of C1q-dependent classical complement activation . |